Articles

Cancer care is one of the fastest growing components of US healthcare costs and is estimated to reach $158 billion by 2020. The American Society of Clinical Oncology (ASCO) Value in Cancer Care Task Force attributes the rising cost of cancer care to several factors, including the overall aging of the population, the introduction of costly new drugs and innovative surgery and radiation techniques, and the adoption of more expensive diagnostic tests.

In a decade of provider risk, the CMS Oncology Payment Models are shifting toward risk management as part of the continued evolution toward integrated networks and bundled payments in healthcare.

Elotzumab’s “double whammy” mechanism of action acts directly on the tumor itself and enhances the activity of natural killer cells to kill the tumor.

Combination treatment with nivolumab and ipilimumab doubled progression-free survival in patients with advanced melanoma, according to CheckMate 067 investigators.

Experts at the AVBCC 5th Annual Conference suggested that retrospective analyses of big data should more effectively differentiate between different approaches to cancer care based on care quality and evidence-based, clinically meaningful outcomes. Data silos can help in the short-term to prioritize process measures.

Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm. Polycythemia vera is characterized by the clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Increased red blood cell mass results in the hyperviscosity of the blood, an increased risk for thrombosis, poor quality of life, and a shortened life expectancy.

Two oncologists from Fox Chase Cancer Center in Philadelphia have added their weight to the growing call for less intensive follow-up of cancer survivors whenever appropriate.

Philadelphia, PA—Although whole genomic sequencing can be done on a patient’s tumor, it does not mean that this will translate to a patient’s getting targeted therapy to identified genetic abnormalities, especially if that patient has pancreatic cancer.

Philadelphia, PA—In an era of personalized care, targeted cancer therapies are on the rise and are expected to reach nearly 60% of the global oncology and hematology drug markets by 2017. By testing for genetic biomarkers, physicians can predict patient response to cancer therapy and identify patients who will benefit most from these treatments, thus serving the 2 purposes of increasing the efficiency of treatment decisions and reducing the use of unnecessary drug prescribing and the associated costs.